Trial Profile
Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-Beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Dermatofibrosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 30 Jul 2007 Status change from recruiting to in progress.
- 24 Aug 2005 New trial record.